IDEXX Laboratories (NASDAQ:IDXX) Sheds 3.1% This Week, as Yearly Returns Fall More in Line With Earnings Growth
IDEXX Laboratories (NASDAQ:IDXX) Sheds 3.1% This Week, as Yearly Returns Fall More in Line With Earnings Growth
While IDEXX Laboratories, Inc. (NASDAQ:IDXX) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 25% in the last quarter. But that doesn't change the fact that the returns over the last five years have been very strong. Indeed, the share price is up an impressive 101% in that time. We think it's more important to dwell on the long term returns than the short term returns. Ultimately business performance will determine whether the stock price continues the positive long term trend.
而 IDEXX 实验室有限公司 纳斯达克股票代码:IDXX)的股东们可能普遍感到高兴,该股最近表现不佳,上个季度股价下跌了25%。但这并不能改变这样一个事实,即过去五年的回报非常强劲。事实上,在那段时间里,股价上涨了令人印象深刻的101%。我们认为,关注长期回报比关注短期回报更为重要。最终,业务表现将决定股价是否延续积极的长期趋势。
Although IDEXX Laboratories has shed US$1.1b from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.
尽管IDEXX Laboratories本周已从市值中减少了11亿美元,但让我们来看看其长期基本面趋势,看看它们是否推动了回报。
See our latest analysis for IDEXX Laboratories
查看我们对 IDEXX 实验室的最新分析
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
虽然市场是一种强大的定价机制,但股价反映了投资者的情绪,而不仅仅是潜在的业务表现。评估公司情绪变化的一种有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。
During five years of share price growth, IDEXX Laboratories achieved compound earnings per share (EPS) growth of 22% per year. This EPS growth is higher than the 15% average annual increase in the share price. So one could conclude that the broader market has become more cautious towards the stock.
在股价增长的五年中,IDEXX Laboratories实现了每年22%的复合每股收益(EPS)增长。每股收益的增长高于股价平均每年增长15%。因此,人们可以得出结论,整个市场对该股变得更加谨慎。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
该公司的每股收益(随着时间的推移)如下图所示(点击查看确切数字)。
We know that IDEXX Laboratories has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.
我们知道IDEXX Laboratories最近提高了利润,但它会增加收入吗?如果你有兴趣,可以看看这个 免费的 显示共识收入预测的报告。
A Different Perspective
不同的视角
It's good to see that IDEXX Laboratories has rewarded shareholders with a total shareholder return of 16% in the last twelve months. That gain is better than the annual TSR over five years, which is 15%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 2 warning signs for IDEXX Laboratories that you should be aware of before investing here.
很高兴看到IDEXX Laboratories在过去十二个月中向股东提供了16%的总股东回报率。这比五年内的年度股东总回报率(15%)要好。因此,看来最近围绕该公司的情绪一直很乐观。鉴于股价势头仍然强劲,可能值得仔细观察该股,以免错过机会。我发现从长远来看,将股价作为业务表现的代表非常有趣。但是,为了真正获得洞察力,我们还需要考虑其他信息。例如,我们发现 IDEXX 实验室有 2 个警告信号 在这里投资之前,你应该注意这一点。
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果你和我一样,那么你会 不 想错过这个 免费的 内部人士正在收购的成长型公司名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。